Vir Biotechnology, Inc. Form 4 (Aug. 12, 2022) — NELSEN ROBERT

Summary

Robert Nelsen, a director of Vir Biotechnology, Inc. (VIR), reports in this Form 4 distributions of common stock dated 08/12/2022, 08/15/2022 and 08/16/2022. On each date ARCH Venture Fund IX, L.P. disposed of 217,781 shares and ARCH Venture Fund IX Overage, L.P. 282,219 shares, described as distributions by a limited partnership to its partners for no consideration, leaving 7,150,475 and 9,266,188 shares. The reporting person acquired 27,489 shares directly on each date, for 377,701 shares owned directly, and 1,684 shares reported as indirect, for 22,115. The form is signed /s/ Mark McDonnell, as Attorney-in-Fact, dated 08/16/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * NELSEN ROBERT (Last) (First) (Middle) 8755 W. HIGGINS ROAD, SUITE 1025 (Street) CHICAGO IL 60631 (City) (State) (Zip) | NELSEN ROBERT | (Last) | (First) | (Middle) | 8755 W. HIGGINS ROAD, SUITE 1025 | CHICAGO | IL | 60631 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below) | X | Director | X | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 08/12/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 08/12/2022 | J (1) | 217,781 | D | $ 0 | 7,586,037 | I | See footnote (2)
Common Stock | 08/12/2022 | J (1) | 282,219 | D | $ 0 | 9,830,626 | I | See footnote (3)
Common Stock | 08/12/2022 | J (1) (4) | 27,489 | A | $ 0 | 322,723 (5) | D
Common Stock | 08/12/2022 | J (1) (4) | 1,684 | A | $ 0 | 18,747 (5) | I | See footnote (5)
Common Stock | 08/15/2022 | J (1) | 217,781 | D | $ 0 | 7,368,256 | I | See footnote (2)
Common Stock | 08/15/2022 | J (1) | 282,219 | D | $ 0 | 9,548,407 | I | See footnote (3)
Common Stock | 08/15/2022 | J (1) (4) | 27,489 | A | $ 0 | 350,212 (5) | D
Common Stock | 08/15/2022 | J (1) (4) | 1,684 | A | $ 0 | 20,431 (5) | I | See footnote (5)
Common Stock | 08/16/2022 | J (1) | 217,781 | D | $ 0 | 7,150,475 | I | See footnote (2)
Common Stock | 08/16/2022 | J (1) | 282,219 | D | $ 0 | 9,266,188 | I | See footnote (3)
Common Stock | 08/16/2022 | J (1) (4) | 27,489 | A | $ 0 | 377,701 (5) | D
Common Stock | 08/16/2022 | J (1) (4) | 1,684 | A | $ 0 | 22,115 (5) | I | See footnote (5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Distribution of Common Stock held by a limited partnership to its partners for no consideration.
2. The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
3. The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
4. Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person.
5. Shares held by a trust for the benefit of family members of the Reporting Person.
By: Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact | 08/16/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2022-08-16_0001062993-22-018155.xml

Size

24,914 bytes

SHA-256

c840b6aa487fe99899d49ad56420bf6a3490a8309a09271936b72e0a3e9c5aaf

Our copy

SEC_VIR_4_filed2022-08-16_0001062993-22-018155.xml

Original

www.sec.gov